Marijuana sativa, a species of marijuana plant, is well known to humankind, with its earliest use in old Chinese society dating as far back as 2700 B.C. (Zuardi, 2006). The use of medical cannabis in China was reported in the world’s oldest pharmacopoeia (Martin et al., 1999). Nonetheless, rate of interest in the duty of cannabis prospered in the late the twentieth century after the acknowledgment of an endogenous cannabinoid system in the mind (Zuardi, 2006; Martin et al., 1999). More lately, research has actually centered on the description and cloning of certain receptors as well as the restorative results of medical cannabis, and also different cannabinoids in the marijuana plant have actually obtained passion (Martin et al., 1999).


Recent researches have actually concentrated on the therapeutic function of clinical cannabis in various conditions. As a result, there is an expanding demand to sum up as well as examine the evidence for its healing and also negative effects as a help to public health policy growth, and also to supply direction as well as inspiration to pharmaceutical study in this area.

Marijuana Hemp Processors – This is the holy grail chance for those checking out marijuana hemp franchising. These are folks who turn hemp into customer products for leisure and medicinal usage.

Cosmetic Products – CBD can be infused in a range of charm and skincare items, from lotions, soaps, and much more. If you are aiming to participate the cannabis hemp craze, this might be your best shot.

Which Franchising Opportunities are offered in Cannabis Hemp Market?

There are plenty of company and franchising chances to explore in the marijuana hemp sector, including:


Cannabis hemp retailers – getting CBD items to consumers in a shop environment presents an excellent franchising opportunity. There plenty of brick-and-mortar and online stores touting CBD products for a variety of uses.


Qualitative synthesis of eligible studies
Schizophrenia and psychosis in Parkinson’s disease
There were three RCTs (164 patients), one clinical trial (27 patients), one case series (three patients), one case report for schizophrenia, and one open-label trial (six patients) for psychosis in Parkinson’s disease (Table 1) (Leweke et al., 2012; Hallak et al., 2010; Boggs et al., 2018; McGuire et al., 2018; Zuardi et al., 2006; Zuardi et al., 1995; Zuardi et al., 2009). Of the seven studies, level 2 evidence was found in three RCTs, level 3 evidence in two clinical trial, and level 4 evidence in one case report and one case series (OCEBM, 2019). Since most of the studies were from level 2 and level 3 evidence, there is Grade B recommendation for schizophrenia. The dose of CBD in these studies ranged from 200 to 1500 mg daily. The highest dose was titrated to 1500 mg daily as reported by Zuardi and colleagues (Zuardi et al., 1995). Irrespective of the study design, three studies reported that CBD alleviated psychotic symptoms and cognitive impairment in patients with chronic cannabis use and Parkinson’s disease (Leweke et al., 2012; Zuardi et al., 1995; Zuardi et al., 2009), while only two RCTs and one clinical trial provided evidence for the effectiveness of CBD among patients with schizophrenia, albeit with mixed results (Leweke et al., 2012; McGuire et al., 2018; Zuardi et al., 2009).